

S_{pO_2}/F_{IO_2} on Presentation as a Predictor for Early Hemodynamic Deterioration in Intermediate Risk Acute Pulmonary Embolism

Lisa Domaradzki, Mehrdad Ghahramani, Ryan Rogers, Mohammed Ruzieh, Ryan Wilson, and Andry Van de Louw

BACKGROUND: Patients with intermediate-risk acute pulmonary embolism are at risk of hemodynamic deterioration, and identification of risk factors for decompensation could guide the administration of thrombolytics. We aimed to assess whether S_{pO_2}/F_{IO_2} on presentation is associated with early hemodynamic deterioration in this population. **METHODS:** A retrospective chart review of subjects admitted between 2006 and 2018 with intermediate-risk pulmonary embolism (hemodynamically stable with right ventricle to left ventricle ratio > 0.9 or tricuspid annular plane systolic excursion < 18 mm). Early hemodynamic deterioration was defined as requirements for vasopressors or rescue thrombolytics within 48 h. Results are presented as median (interquartile range). **RESULTS:** A total of 178 subjects were included. Early hemodynamic deterioration occurred in 13% of the subjects and was associated with a median (interquartile range) lower S_{pO_2}/F_{IO_2} on presentation in univariate analysis (243 [123–275] versus 438 [335–457], $P < .001$) and in a multivariate analysis, including heart rate and right ventricle to left ventricle ratio as covariates (odds ratio 0.992, 95% CI 0.987–0.996; $P < .001$). The initial S_{pO_2}/F_{IO_2} predicted hemodynamic deterioration with an area under the receiver operating characteristic curve of 0.81 and a threshold of 260 was associated with a sensitivity of 74% and specificity of 88%. Sensitivity analyses restricted to subjects with hypoxemia on presentation and subjects with an elevated troponin level led to similar results. **CONCLUSIONS:** In intermediate-risk pulmonary embolism, S_{pO_2}/F_{IO_2} on presentation can help predict the risk of early hemodynamic deterioration. *Key words:* pulmonary embolism; hypoxia; right ventricular failure; shock; oxygenation; acute respiratory failure. [Respir Care 0;0(0):1–•. © 0 Daedalus Enterprises]

Introduction

Venous thromboembolic disease, including deep venous thrombosis and pulmonary embolism, is a frequent disease,

Drs Domaradzki, Rogers, and Van de Louw are affiliated with the Division of Pulmonary and Critical Care Medicine, Pennsylvania State University College of Medicine and Milton S Hershey Medical Center, Hershey, Pennsylvania. Drs Ghahramani, Ruzieh, and Wilson are affiliated with the Division of Cardiology, Heart and Vascular Institute, Pennsylvania State University College of Medicine and Milton S Hershey Medical Center, Hershey, Pennsylvania.

The authors have disclosed no conflicts of interest.

Correspondence: Andry Van de Louw MD PhD, Division of Pulmonary and Critical Care Medicine, Milton S Hershey Medical Center, 500 University Drive, Hershey, PA 17033. E-mail: avandelouw@pennstatehealth.psu.edu.

DOI: 10.4187/respcare.06797

with an annual incidence of 100–200 cases per 100,000 people.¹ Patients with acute pulmonary embolism have a 3-month mortality of $\sim 15\%$ ² but present with a wide variety of disease severity. At one extreme of the spectrum, high-risk or massive pulmonary embolism, defined by the presence of shock or hypotension despite intravenous fluid administration, is associated with a 58% mortality² and is a recognized indication for thrombolytic therapy,¹ which decreases the rate of recurrent pulmonary embolism or death.³ The other side of the spectrum includes patients who are normotensive with no sign of right-ventricular dysfunction and low-risk scores (such as simplified pulmonary embolism severity index (sPESI)⁴), whose mortality is $< 1\%$.⁵ In between, patients who are normotensive and with signs of right-ventricular dysfunction (intermediate-risk or submassive pulmonary embolism) represent a challenge: their mortality is lower than in patients with hypotension but remains concerning ($\sim 8\%$).⁶ There currently is no proven benefit of thrombolytics on survival in these patients and, therefore, no recommendation about their use,

S_{pO_2}/F_{IO_2} IN ACUTE PULMONARY EMBOLISM

which requires a case-by-case evaluation of the benefits/risk ratio.

Arterial hypoxemia is common during acute pulmonary embolism, being observed in 14–43% of unselected patients with acute pulmonary embolism.^{7–10} Its mechanisms mainly involve a ventilation/perfusion ratio mismatch,¹¹ but intrapulmonary shunting¹² or low venous P_{O_2} ¹³ due to decreased cardiac output may also be contributing in selected patients. The severity of hypoxemia has generally been considered to be related to the degree of arterial obstruction¹⁴ despite the lack of strong evidence and the observation that this may not be true in the presence of shock.¹⁵ Hypoxemia has been associated with the presence of right-ventricular dysfunction,^{16,17} and several studies reported more-frequent and/or severe hypoxemia in unselected subjects with pulmonary embolism and with a fatal outcome, although hypoxemia was not an independent predictor of mortality for most of these studies.^{7,8,10,18}

A naturally arising question is whether hypoxemia on presentation is associated with an increased risk of hemodynamic deterioration in intermediate-risk pulmonary embolism. Indeed, in submassive pulmonary embolism not treated with thrombolytics, ~10% of patients develop worsening shock within a few days;¹⁸ these patients may benefit from delayed thrombolytic therapy but mortality in this setting is significant, and tools to predict this clinical deterioration and perhaps guide early administration of thrombolytics are lacking. The objective of this study was to assess the relationship between S_{pO_2}/F_{IO_2} on presentation and early (<48 h) hemodynamic deterioration in subjects with intermediate-risk acute pulmonary embolism.

Methods

This retrospective study was approved by the Pennsylvania State University Institutional Review Board (8288), and informed consent was waived due to the retrospective design of data collection. All adults (ages > 18 y) admitted as inpatients between January 1, 2006, and March 30, 2018, with (1) an *International Classification of Diseases, 9th Revision* or an *International Classification of Diseases, 10th Revision* diagnosis of acute pulmonary embolism; (2) a systolic blood pressure > 90 mm Hg at the time of pulmonary embolism diagnosis; (3) an echocardiogram performed during their admission; (4) signs of right ventricular dysfunction, as defined by a right ventricle to left ventricle ratio of >0.9 and/or tricuspid annular plane systolic excursion < 18 mm were included.

Data collected included demographics, main comorbidities, cardiac biomarkers when available, results of lower-extremity duplex, computed tomography pulmonary angiography, and echocardiogram. Vital signs and O_2 requirements on presentation were collected as follows: for patients admitted through the emergency department,

QUICK LOOK

Current knowledge

In patients with intermediate-risk acute pulmonary embolism, identification of risk factors for early hemodynamic deterioration would help to assess the benefits/risk ratio of thrombolytics. Hypoxemia is common during acute pulmonary embolism and has been assumed to be related to the degree of arterial obstruction, which suggests that the severity of hypoxemia on presentation could be predictive of subsequent hemodynamic deterioration in initially stable patients.

What this paper contributes to our knowledge

In this retrospective study of subjects with intermediate-risk pulmonary embolism, we observed that S_{pO_2}/F_{IO_2} on presentation was significantly associated with hemodynamic deterioration within 48 h, in univariate and multivariate analysis. S_{pO_2}/F_{IO_2} seemed to perform better than heart rate or right ventricle to left ventricle ratio in predicting subsequent hemodynamic deterioration.

the first available set of parameters was taken into account; for in-patients, the parameters were recorded at the closest time to diagnostic suspicion and before any intervention. S_{pO_2}/F_{IO_2} on presentation was computed by using a conversion table as follows: for subjects who received O_2 via a nasal cannula, O_2 flows of 1, 2, 3, 4, 5, and 6 L/min were converted to F_{IO_2} of 0.24, 0.28, 0.32, 0.36, 0.40, and 0.44, respectively, as previously published.¹⁹ All the subjects who received O_2 via a non-rebreather mask had a flow of 15 L/min, which was converted to a F_{IO_2} of 0.80 based on available studies.²⁰ The simplified pulmonary embolism severity index score was calculated.²¹ Early hemodynamic deterioration was defined by the requirement for vasopressors or use of rescue thrombolytics within 48 h of diagnosis. Day 30 mortality was collected.

Statistical Analysis

Data were analyzed by using the *r* statistical package (<https://www.R-project.org/>, Accessed April 24, 2019) and are presented as median (interquartile range [IQR]) for quantitative variables and number (percentage) for categorical variables. Continuous and categorical variables were compared between groups with the Wilcoxon rank-sum test and Fisher exact test, respectively. A multivariate logistic regression model was used to predict the occurrence of early hemodynamic deterioration with covariates selected based on univariate analysis and clinical relevance. We performed a receiver operating characteristic

S_{pO_2}/F_{IO_2} IN ACUTE PULMONARY EMBOLISM

Table 1. Comparison of Subject Characteristics Based on the Occurrence of Hemodynamic Deterioration Within 48 Hours of Intermediate-Risk Acute Pulmonary Embolism Diagnosis

| Parameter | Subjects Without Early Deterioration (<i>n</i> = 155) | Subjects With Early Deterioration (<i>n</i> = 23) | <i>P</i> |
|--|--|--|----------|
| Age, median (IQR) y | 66 (56–74) | 61 (44–69) | .06 |
| Men/women, <i>n</i> | 84/71 | 15/8 | .37 |
| BMI, median (IQR) kg/m ² | 30 (26–35) | 31 (26–40) | .49 |
| Malignancy, <i>n</i> (%) | 55 (35) | 6 (26) | .48 |
| Previous thromboembolic disease, <i>n</i> (%) | 36 (23) | 4 (17) | .79 |
| CAD/CHF, <i>n</i> (%) | 48 (31) | 5 (22) | .47 |
| COPD/OSAS, <i>n</i> (%) | 26 (17) | 3 (13) | .77 |
| Vital signs on presentation | | | |
| Heart rate, median (IQR) beats/min | 99 (87–111) | 121 (108–129) | <.001 |
| Frequency, median (IQR) breaths/min | 20 (18–24) | 24 (18–30) | .24 |
| SBP, median (IQR) mm Hg | 132 (118–148) | 136 (112–146) | .58 |
| S_{pO_2} , median (IQR) % | 95 (92–97) | 93 (92–97) | .88 |
| O ₂ requirement, <i>n</i> (%) | 48 (31) | 18 (78) | <.001 |
| Laboratory values (first 24 h), median (IQR) | | | |
| Troponin I, ng/mL | 0.085 (0.027–0.448) | 0.28 (0.11–0.56) | .09 |
| Troponin T, ng/mL | 0.07 (0.02–0.16) | 0.07 (0.03–0.19) | .84 |
| NT-pro BNP, pg/mL | 1470 (300–3875) | 2100 (540–4395) | .44 |
| Imaging results | | | |
| Lobar or saddle pulmonary embolism, <i>n</i> (%) | 121 (78) | 21 (84) | .17 |
| RV/LV, median (IQR) | 1.16 (0.96–1.38) | 1.4 (1.2–1.7) | .008 |
| LV ejection fraction, median (IQR) % | 65 (60–65) | 65 (55–70) | .75 |
| RV basal diastolic diameter, median (IQR) cm | 4.4 (3.7–5.0) | 5.1 (4.3–5.5) | .02 |
| TAPSE, median (IQR) cm | 1.6 (1.3–2.1) | 1.3 (1.0–1.9) | .07 |
| Systolic pulmonary arterial pressure, mm Hg | 45 (35–55) | 49 (45–55) | .46 |
| IVC diameter, median (IQR) cm | 2 (1.5–2.4) | 2.1 (1.7–2.3) | .75 |
| IVC collapsibility, <i>n</i> (%) | 86 (67) | 7 (58) | .54 |
| McConnell sign, <i>n</i> (%) | 16 (10) | 4 (17) | .30 |
| Positive LE duplex, <i>n</i> (%) | 39 (80) | 7 (78) | >.99 |
| sPESI \geq 1, <i>n</i> (%) | 102 (66) | 18 (78) | .34 |
| S_{pO_2}/F_{IO_2} , median (IQR) | 438 (335–457) | 243 (123–275) | <.001 |
| Day 30 mortality, <i>n</i> (%) | 22 (14) | 7 (30) | .07 |

IQR = interquartile range

BMI = body mass index

CAD = coronary artery disease

CHF = congestive heart failure

OSAS = obstructive sleep apnea syndrome

SBP = systolic blood pressure

NT-pro BNP = N-terminal pro-brain natriuretic peptide

RV = right ventricle

LV = left ventricle

TAPSE = tricuspid annular plane systolic excursion

IVC = inferior vena cava

LE = lower extremity

sPESI = simplified pulmonary embolism severity index

analysis to assess the performance of S_{pO_2}/F_{IO_2} and heart rate on presentation as predictors of early hemodynamic deterioration. All tests were 2-sided, with $P < .05$ being considered for statistical significance.

Results

We included 178 subjects with intermediate-risk acute pulmonary embolism. Characteristics of the subjects ac-

cording to the development of early hemodynamic deterioration are detailed in Table 1. Twenty-three subjects (13% of the population) subsequently developed hemodynamic deterioration: on presentation, they had a higher heart rate, right ventricle to left ventricle ratio, right-ventricular basal diastolic diameter, and lower tricuspid annular plane systolic excursion, and were more frequently administered oxygen compared with the subjects who remained stable. No difference in breathing frequency but significantly lower


S_{pO_2}/F_{IO_2} IN ACUTE PULMONARY EMBOLISM

Fig. 1. Comparison of the distribution of S_{pO_2}/F_{IO_2} (A), heart rate (B), and right ventricle to left ventricle (RV/LV) ratio (C) on admission in subjects with intermediate-risk acute pulmonary embolism according to the development of hemodynamic deterioration within 48 h of diagnosis. *Heart rate and RV/LV were significantly higher and S_{pO_2}/F_{IO_2} was significantly lower in subjects with early hemodynamic deterioration.

Table 2. Multivariate Logistic Regression Predicting the Development of Hemodynamic Deterioration Within 48 Hours of Diagnosis in 178 Subjects With Acute Pulmonary Embolism

| Variable | <i>P</i> | Odds Ratio | 95% CI |
|---|----------|------------|--------------|
| Heart rate on presentation | .02 | 1.032 | 1.007–1.061 |
| S_{pO_2}/F_{IO_2} on presentation | <.001 | 0.992 | 0.987–0.996 |
| Right ventricle to left ventricle ratio | .07 | 3.157 | 0.908–11.564 |

S_{pO_2}/F_{IO_2} was observed in the subjects who later deteriorated (median [IQR] 243 [123–275] versus 438 [335–457], $P < .001$). Their 30-d mortality tended to be higher (30% versus 14%, $P = .07$). The subjects who remained stable and those who deteriorated had similar proportion of saddle or lobar pulmonary embolism, and no difference in S_{pO_2}/F_{IO_2} was observed among the subjects with saddle, lobar, segmental, or subsegmental pulmonary embolism. The distribution of S_{pO_2}/F_{IO_2} , heart rate, and right ventricle to left ventricle ratio in subjects with and without early hemodynamic deterioration are summarized in Figure 1. In multivariate analysis, significant predictors of early hemodynamic deterioration were heart rate (odds ratio 1.032, 95% CI 1.007–1.061; $P = .02$) and S_{pO_2}/F_{IO_2} (odds ratio 0.992, 95% CI 0.987–0.996; $P < .001$) on presentation (Table 2).

In Figure 2, receiver operating characteristic curves display the performance of S_{pO_2}/F_{IO_2} and the heart rate as predictors of hemodynamic deterioration within 48 h of diagnosis: the area under the receiver operating characteristic curve was 0.81 for S_{pO_2}/F_{IO_2} and 0.75 for heart rate ($P = .45$). A threshold of $S_{pO_2}/F_{IO_2} < 260$ predicted early hemodynamic deterioration, with a specificity of 88%, sensitivity of 74%, positive predictive value of 47%, and neg-




Fig. 2. Receiver operating characteristic curves, describing the performance of S_{pO_2}/F_{IO_2} and heart rate as predictors of hemodynamic deterioration within 48 h of the diagnosis of acute intermediate-risk pulmonary embolism. Areas under the receiver operating characteristic curve were 0.81 and 0.75 for S_{pO_2}/F_{IO_2} and heart rate, respectively ($P = .12$).

ative predictive value of 96%, whereas these values were 66%, 78%, 74% and 95%, respectively, for a heart rate of >107 beats/min. When combining the 2 parameters in a score defined by $(S_{pO_2}/F_{IO_2})/\text{heart rate}$, the area under the receiver operating characteristic curve increased to 0.85 but the performance of the combined score was not significantly different from S_{pO_2}/F_{IO_2} alone ($P = .12$), and the sensitivity and specificity achieved were similar.

In a sensitivity analysis, we included only the subjects with hypoxemia on presentation, as defined by $F_{IO_2} \geq 0.40$ and/or $S_{pO_2} \leq 90\%$ ($n = 59$). Fourteen of these subjects

S_{pO_2}/F_{IO_2} IN ACUTE PULMONARY EMBOLISM

developed early hemodynamic deterioration compared with 3 of 75 subjects with initial O_2 requirements $< 28\%$ (2 L/min via nasal cannula) and $S_{pO_2} \geq 94\%$ ($P = .001$). When compared with the hypoxemic subjects who remained stable, the subjects who subsequently decompensated had a higher heart rate (116 [107–134] beats/min versus 100 [82–116] beats/min, $P = .01$) and right ventricle to left ventricle ratio (1.55 [1.33–1.90] versus 1.10 [0.92–1.36], $P = .008$) and lower S_{pO_2}/F_{IO_2} (128 [104–217] versus 343 [180–405], $P = .002$) on presentation, as in the analysis on the whole population. In multivariate analysis, S_{pO_2}/F_{IO_2} remained significantly associated with early hemodynamic deterioration (odds ratio 0.988, 95% CI 0.975–0.996; $P = .01$), whereas the other covariates were not.

Another sensitivity analysis excluded, among subjects with troponin available ($n = 112$), those with normal levels (intermediate-low risk pulmonary embolism as per recent European Society of Cardiology guidelines,¹ $n = 46$), who had a median (IQR) S_{pO_2}/F_{IO_2} of 436 [314–452] versus 398 [265–451] for subjects with elevated troponin (intermediate-high risk, $n = 66$) ($P = .17$). Indeed, only 9% of these subjects at intermediate-low risk developed early hemodynamic deterioration versus 24% for subjects with intermediate-high risk ($P = .03$). Again, subjects with intermediate-high risk who subsequently deteriorated had significantly lower S_{pO_2}/F_{IO_2} on presentation compared with subjects who remained stable (median [IQR] 234 [122–417] versus 410 [338–452], $P = .003$). S_{pO_2}/F_{IO_2} remained an independent predictor of early hemodynamic deterioration in this subgroup in multivariate analysis (odds ratio 0.992, 95% CI 0.985–0.997; $P = .008$).

Discussion

The main findings of this study were that hypoxemia on presentation, as measured by S_{pO_2}/F_{IO_2} , is associated with an increased risk of early hemodynamic deterioration in subjects with intermediate-risk acute pulmonary embolism and that S_{pO_2}/F_{IO_2} could be a better predictor of clinical deterioration compared with initial heart rate or echocardiographic parameters. In our population of 178 subjects with intermediate-risk acute pulmonary embolism, 13% developed hemodynamic deterioration within 48 h. This proportion is consistent with published data: a recent study reported that 9% of 298 subjects with all-risk pulmonary embolism had severe clinical deterioration within 5 d,⁹ and other investigators reported 10% of shock developing during the acute phase among 65 subjects who were normotensive and with right-ventricular dysfunction.¹⁸ Although intermediate-risk pulmonary embolism is associated with an overall hospital mortality of $\sim 8\%$,⁶ data on mortality for the subset of subjects initially stable and who subsequently deteriorate is scarce: we observed a 30% mortality

among 23 subjects, whereas, in the study by Grifoni et al,¹⁸ 3 of 6 subjects died.

What is the rationale for investigating hypoxemia on presentation as a predictor for subsequent hemodynamic deterioration? Given the uncertainty about indications for thrombolytics and the significant mortality associated with intermediate-risk pulmonary embolism, identifying predictors of clinical deterioration is essential to administer thrombolytics on time in patients likely to deteriorate while preventing bleeding complications associated with thrombolytics (up to 22% of major bleeding in the study by Konstantinides et al²²) in patients likely to remain stable. The hypothesis that hypoxemia on presentation may be predictive of secondary hemodynamic decompensation is based on pathophysiologic and indirect clinical evidence: the mechanisms of hypoxemia during acute pulmonary embolism involve mainly ventilation/perfusion ratio mismatch and low venous P_{O_2} ^{11,13,23} secondary to decreased cardiac output. One, therefore, would expect acute pulmonary embolism to proportionally affect cardiac output and oxygenation, even when systolic arterial pressure is maintained. In a series of 20 subjects free of previous cardiopulmonary disease and diagnosed with acute pulmonary embolism, McIntyre and Sasahara¹⁴ observed a good correlation between P_{aO_2} and both cardiac index and the degree of pulmonary vascular obstruction measured by pulmonary angiography. Clinical studies also showed an association between hypoxemia and right-ventricular dysfunction^{16,18} or elevated troponin levels,¹⁰ both markers of the hemodynamic impact of acute pulmonary embolism.

Clinical studies that investigated the relationship between hypoxemia on presentation and outcome during acute pulmonary embolism brought mixed results: most studies reported lower P_{aO_2} in subjects with worse outcomes in all-risk^{8,16} or intermediate-risk acute pulmonary embolism²⁴; however, hypoxemia was not an independent predictor of mortality in multivariate analyses.¹⁸ In a study that focused on factors associated with early (5 d) clinical deterioration in 298 subjects with all-risk acute pulmonary embolism, factors independently associated with a severe outcome (as defined by the occurrence of either death, advanced cardiac life support, ventricular tachycardia or fibrillation, mechanical ventilation, vasopressors, thrombolysis, or thrombectomy) were systolic blood pressure < 90 mm Hg in the emergency department, elevated N-terminal pro-brain natriuretic peptide and right-ventricular strain on echocardiogram.⁹ Hypoxemia, as defined by a lowest S_{pO_2} of $< 95\%$ in the emergency department, was more frequent in the subjects who subsequently developed severe outcome within 5 d but was not associated with severe outcome in multivariate analysis.⁹

However, this study included subjects with all-risk pulmonary embolism (only 20% had echocardiogram), and a lowest S_{pO_2} of $< 95\%$ in the emergency department was

S_{pO_2}/F_{IO_2} IN ACUTE PULMONARY EMBOLISM

the only marker of hypoxemia used, which may have affected the conclusions. In another study on 201 subjects with low- or intermediate-risk pulmonary embolism, initial hypoxemia ($P_{aO_2} < 60$ mm Hg on room air) was associated with in-hospital and 3-month all-cause mortality in univariate analysis; however, it was not significantly associated with all-cause mortality in multivariate analysis and was not predictive of specifically pulmonary embolism-related death or clinical deterioration (rescue thrombolysis, vasopressors, mechanical ventilation, or cardiopulmonary resuscitation).⁸ None of the variables investigated (troponin, N-terminal pro-brain natriuretic peptide, D-dimer, right-ventricular dysfunction) was actually associated with clinical deterioration or death due to pulmonary embolism.⁸

Whether hypoxemia on presentation can more specifically predict early hemodynamic deterioration in submassive pulmonary embolism remained unclear. A study that addressed the association between hypoxemia and outcome in 124 subjects with acute intermediate-risk pulmonary embolism showed that alveolar-arterial oxygen gradient was a good predictor of 90-d mortality²⁴; however, the investigators did not specifically address early clinical deterioration; moreover, hypoxemia was not really diagnosed on presentation, as arterial blood gases were collected within 24 h, and one cannot exclude that some subjects had arterial blood gases collected while they were already deteriorating.

Analysis of our results indicated that hypoxemia on presentation was associated with requirements for vasopressors or rescue thrombolytics within 48 h in subjects with intermediate-risk pulmonary embolism; S_{pO_2}/F_{IO_2} was associated with early deterioration in our population, including in multivariate and sensitivity analyses, and seemed to be a reliable predictor of hemodynamic deterioration. Mortality as the outcome was not the focus of this study, but the fact that hypoxemia on presentation seemed associated with hemodynamic deterioration, whereas the literature does not definitely support its association with mortality, deserves further consideration. First, although acute pulmonary embolism is directly the main cause of death in this setting, studies reported other causes of early death in pulmonary embolism (sepsis, cancer, heart failure),^{8,18} so that an impact of hypoxemia on early hemodynamic deterioration would not necessarily translate into mortality. Second, potentially strong interactions between hypoxemia and other covariates, such as right-ventricular dysfunction or cardiac biomarkers, make it difficult to isolate the effect of hypoxemia on mortality, even with sophisticated multivariate analyses.

Limitations of our study are mostly related to its retrospective design. Data collection based on chart review, the lack of protocol to administer thrombolytics or vasopressors, and the arbitrary time window of 48 h used to define

hemodynamic deterioration are potential sources of bias. The lack of arterial blood gases to corroborate the degree of hypoxemia and to assess the predictive value of other blood gas parameters (pH, P_{CO_2} , HCO_3^-) is another limitation. At our institution, arterial blood gases are not routinely performed in patients with acute pulmonary embolism, one reason being to avoid arterial puncture before potential thrombolytics administration; results were available for only 78 of the 178 subjects analyzed, with various timing of collection, which made their interpretation with respect to clinical deterioration difficult. We, therefore, chose not to present these results and rather investigated the value of S_{pO_2}/F_{IO_2} , a noninvasive parameter readily available for all the subjects. S_{pO_2}/F_{IO_2} has been used and validated in several studies to assess the severity of hypoxemia as a surrogate for P_{aO_2}/F_{IO_2} in subjects on mechanical ventilation^{25,26} and has also been used in subjects not on mechanical ventilation who were on wards to predict the development of ARDS²⁷ or ICU transfer.^{28,29} Finally, one could argue about the use of an estimated F_{IO_2} to compute S_{pO_2}/F_{IO_2} in subjects not on mechanical ventilation; indeed, our retrospective design only allowed us to collect O_2 flow, and several factors related to subjects' respiratory pattern may have affected the O_2 flow/ F_{IO_2} relationship. However, we used conversion tables based on published studies,^{19,20} and several other investigators used similar conversions^{30,31} due to the difficulty in accurately measuring F_{IO_2} in subjects who are spontaneously breathing.

Conclusions

In 178 subjects with intermediate-risk acute pulmonary embolism, S_{pO_2}/F_{IO_2} on presentation was significantly associated with hemodynamic deterioration within 48 h, which occurred in 13% of the subjects; an S_{pO_2}/F_{IO_2} threshold of 260 was the best predictor of decompensation and might be used to help assess the benefits-risk balance of thrombolytics in this setting. Prospective observational studies would be warranted to confirm these results.

REFERENCES

1. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J* 2014;35(43):3033-3069, 3069a-3069k.
2. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). *Lancet* 1999;353(9162):1386-1389.
3. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. *Circulation* 2004;110(6):744-749.

S_{pO_2}/F_{IO_2} IN ACUTE PULMONARY EMBOLISM

4. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, et al. Derivation and validation of a prognostic model for pulmonary embolism. *Am J Respir Crit Care Med* 2005;172(8):1041-1046.
5. Zhou XY, Ben SQ, Chen HL, Ni SS. The prognostic value of pulmonary embolism severity index in acute pulmonary embolism: a meta-analysis. *Respir Res* 2012;13:111.
6. Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. *J Am Coll Cardiol* 1997;30(5):1165-1171.
7. Meneveau N, Ming LP, Séronde MF, Mersin N, Schiele F, Caulfield F, et al. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. *Eur Heart J* 2003;24(15):1447-1454.
8. Bova C, Pesavento R, Marchiori A, Palla A, Enea I, Pengo V, et al.; TELESIO Study Group. Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up. *J Thromb Haemost* 2009;7(6):938-944.
9. Kabrhel C, Okechukwu I, Hariharan P, Takayesu JK, MacMahon P, Haddad F, Chang Y. Factors associated with clinical deterioration shortly after PE. *Thorax* 2014;69(9):835-842.
10. Giannitsis E, Müller-Bardorff M, Kurowski V, Weidtmann B, Wiegand U, Kampmann M, Katus HA. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. *Circulation* 2000;102(2):211-217.
11. Santolucando A, Prediletto R, Fornai E, Formichi B, Begliomini E, Giannella-Neto A, Giuntini C. Mechanisms of hypoxemia and hypocapnia in pulmonary embolism. *Am J Respir Crit Care Med* 1995;152(1):336-347.
12. D'Alonzo GE, Bower JS, DeHart P, Dantzker DR. The mechanisms of abnormal gas exchange in acute massive pulmonary embolism. *Am Rev Respir Dis* 1983;128(1):170-172.
13. Manier G, Castaing Y, Guenard H. Determinants of hypoxemia during the acute phase of pulmonary embolism in humans. *Am Rev Respir Dis* 1985;132(2):332-338.
14. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. *Am J Cardiol* 1971;28(3):288-294.
15. Jardin F, Gurdjian F, Desfonds P, Fouilladieu JL, Margairaz A. Hemodynamic factors influencing arterial hypoxemia in massive pulmonary embolism with circulatory failure. *Circulation* 1979;59(5):909-912.
16. Subramanian M, Ramadurai S, Arthur P, Gopalan S. Hypoxia as an independent predictor of adverse outcomes in pulmonary embolism. *Asian Cardiovasc Thorac Ann* 2018;26(1):38-43.
17. Braude S, Martens-Nielsen J. Severe refractory hypoxaemia in sub-massive pulmonary embolism: a surrogate marker of severe right ventricular dysfunction and indication for thrombolysis. *Intern Med J* 2012;42(6):712-715.
18. Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camaiti A, Santoro G, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. *Circulation* 2000;101(24):2817-2822.
19. Coudroy R, Frat JP, Boissier F, Contou D, Robert R, Thille AW. Early identification of acute respiratory distress syndrome in the absence of positive pressure ventilation: implications for revision of the Berlin Criteria for Acute Respiratory Distress Syndrome. *Crit Care Med* 2018;46(4):540-546.
20. Chanques G, Riboulet F, Molinari N, Carr J, Jung B, Prades A, et al. Comparison of three high flow oxygen therapy delivery devices: a clinical physiological cross-over study. *Minerva Anestesiol* 2013;79(12):1344-1355.
21. Jiménez D, Aujesky D, Moores L, Gomez V, Lobo JL, Uresandi F, et al.; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. *Arch Intern Med* 2010;170(15):1383-1389.
22. Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. *Circulation* 1997;96(3):882-888.
23. Huet Y, Lemaire F, Brun-Buisson C, Knaus WA, Teisseire B, Payen D, Mathieu D. Hypoxemia in acute pulmonary embolism. *Chest* 1985;88(6):829-836.
24. Ince O, Altintas N, Findik S, Sariaydin M. Risk stratification in submassive pulmonary embolism via alveolar-arterial oxygen gradient. *Hippokratia* 2014;18(4):333-339.
25. Pisani L, Roozeman JP, Simonis FD, Giangregorio A, van der Hoeven SM, Schouten LR, et al.; MARS consortium. Risk stratification using S_{pO_2}/F_{IO_2} and PEEP at initial ARDS diagnosis and after 24 h in patients with moderate or severe ARDS. *Ann Intensive Care* 2017;7(1):108.
26. Brown SM, Duggal A, Hou PC, Tidswell M, Khan A, Exline M, et al.; National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. Nonlinear imputation of P_{aO_2}/F_{IO_2} from S_{pO_2}/F_{IO_2} among mechanically ventilated patients in the ICU: a prospective, observational study. *Crit Care Med* 2017;45(8):1317-1324.
27. Festic E, Bansal V, Kor DJ, Gajic O, US Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG-LIPS). S_{pO_2}/F_{IO_2} ratio on hospital admission is an indicator of early acute respiratory distress syndrome development among patients at risk. *J Intensive Care Med* 2015;30(4):209-216.
28. Kwack WG, Lee DS, Min H, Choi YY, Yun M, Kim Y, et al. Evaluation of the S_{pO_2}/F_{IO_2} ratio as a predictor of intensive care unit transfers in respiratory ward patients for whom the rapid response system has been activated. *PLoS One* 2018;13(7):e0201632.
29. Kim WY, Lee J, Lee JR, Jung YK, Kim HJ, Huh JW, et al. A risk scoring model based on vital signs and laboratory data predicting transfer to the intensive care unit of patients admitted to gastroenterology wards. *J Crit Care* 2017;40:213-217.
30. Riviello ED, Kiviri W, Twagirumugabe T, Mueller A, Banner-Goodspeed VM, Officer L, et al. Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the Berlin Definition. *Am J Respir Crit Care Med* 2016;193(1):52-59.
31. Simon M, Wachs C, Braune S, de Heer G, Frings D, Kluge S. High-flow nasal cannula versus bag-valve-mask for preoxygenation before intubation in subjects with hypoxemic respiratory failure. *Respir Care* 2016;61(9):1160-1167.